Last reviewed · How we verify
NCT03836144
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
trial testing Potassium citrate in Cystinuria in 63 participants. Completed in 31 December 2020.
31 January 2020
Quick facts
| Lead sponsor | European Georges Pompidou Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 2 April 2015 |
| Primary completion | 31 January 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Potassium citrate — full drug profile →
Conditions studied
- Cystinuria — all drugs for Cystinuria →
- Renal Lithiasis — all drugs for Renal Lithiasis →
- Glomerulonephritis — all drugs for Glomerulonephritis →
- Interstitial Nephritis — all drugs for Interstitial Nephritis →
Sponsor
European Georges Pompidou Hospital
Who can join
18 and older, any sex, with Cystinuria or Renal Lithiasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It has recently been described the presence of a urinary inflammatory signature in patients with cystinuria, the most common cause of renal lithiasis of genetical origin. These data are very innovative in this pathology but deserve further studies to establish the specificity of this inflammatory signature in patients with cystinuria compared to other nephropathies and other renal lithiasis diseases. Moreover, the effect of the usual treatment of cystinuria (namely urine alkalanization) on urinary inflammatory biomarkers deserves to be tested. The objectives of the present study are: i) To study the urinary inflammatory profile by mass spectrometry (a very efficient tool to detect and identify proteins) in patients with cystinuria and in patients with lithiasis of other origin and in patients with inflammatory renal disease ; ii) To study the potential effect of urine alkalinazation with potassium citrate (usual treatment according to European recommendations) on the inflammatory signature of patients with cystinuria. To this aim, urine of non treated cystinuric patients will be collected before treatement initiation and 3 months after the start of the alkalizing treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of urine alkalization on urinary inflammatory markers in cystinuric patients.
Prot-Bertoye C, Jung V, Tostivint I, Roger K, et al · · 2024 · PMID 38510798 · DOI 10.1093/ckj/sfae040
Verify or expand the search:
- PubMed search for NCT03836144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Potassium citrate
Trials testing the same drug.
- NCT05389995 — Potassium Citrate and Crystal Light Lemonade · NA · active not recruiting
- NCT02731820 — Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia · NA · completed
Other recruiting trials for Cystinuria
Currently open trials in the same condition.
- NCT06065852 — National Registry of Rare Kidney Diseases · recruiting
Other European Georges Pompidou Hospital trials
Trials by the same sponsor.
- NCT07059715 — Mic Mac: Micro- and Macrocirculatory Assessment During Cardiac Surgery in Patients at Risk of Vasoplegic Syndrome: A Pro · recruiting
- NCT04407858 — Cardiovascular Complications of Carfilzomib · unknown
- NCT04407845 — Atrial Fibrillation in Patients Receiving Ibrutinib · unknown
- NCT07093320 — Saving Limbs After Cancer: Blood Vessel and Soft Tissue Reconstruction Following Sarcoma Surgery in the Legs · completed
- NCT04591509 — Predictability of Echographic Excursion of the Diaphragm for Intubation in COPD- Patients With Acute Respiratory Failure · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03836144 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Georges Pompidou Hospital
- Last refreshed: 22 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03836144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing